SCHEMBL3012685

SCHEMBL3012685

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4c(C)cc(C)cc4C)CC3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MAPT P10636 5/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
RECQL P46063 2/20 0.42
USP2 O75604 1/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 2/20 0.40
MAPK1 P28482 2/20 0.40
PKM P14618 1/20 0.40
TP53 P04637 1/20 0.40
ALDH1A1 P00352 4/20 0.39
GAA P10253 2/20 0.39
ATM Q13315 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011341 0.91 NPSR1 (0.42) KMT2AMAPTL3MBTL1RECQLUSP2
SCHEMBL2999629 0.91 NPSR1 (0.45) KMT2AMAPTNPSR1TSHRMEN1
SCHEMBL3008304 0.91 LMNA (0.48) KMT2APOLBNPSR1TSHRMEN1
SCHEMBL3019426 0.90 KMT2A (0.45) KMT2AMAPTL3MBTL1RECQLUSP2
SCHEMBL3001008 0.90 MAPT (0.49) KMT2AMAPTRECQLUSP2HSD17B10
SCHEMBL3011629 0.89 NPSR1 (0.43) KMT2AMAPTNPSR1TSHRMEN1
SCHEMBL3009944 0.89 SMN1; SMN2 (0.44) KMT2AMAPTRECQLUSP2HSD17B10
SCHEMBL3008378 0.88 EPHX2 (0.47) KMT2AMAPTNPSR1TSHRMEN1
SCHEMBL3016140 0.88 EBP (0.48) KMT2AMAPTL3MBTL1RECQLNPSR1
SCHEMBL3653241 0.88 EPHX2 (0.42) KMT2AMAPTL3MBTL1RECQLUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MAPT 18/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.